Compare HD & AZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HD | AZN |
|---|---|---|
| Founded | 1978 | 1992 |
| Country | United States | United Kingdom |
| Employees | N/A | 96100 |
| Industry | RETAIL: Building Materials | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 377.5B | 311.3B |
| IPO Year | 1997 | N/A |
| Metric | HD | AZN |
|---|---|---|
| Price | $318.15 | $201.08 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 23 | 1 |
| Target Price | ★ $423.00 | N/A |
| AVG Volume (30 Days) | ★ 3.4M | 1.7M |
| Earning Date | 05-19-2026 | 04-28-2026 |
| Dividend Yield | ★ 2.85% | 1.58% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 14.23 | N/A |
| Revenue | ★ $66,176,000,000.00 | N/A |
| Revenue This Year | $7.13 | $10.35 |
| Revenue Next Year | $4.09 | $6.43 |
| P/E Ratio | ★ $22.94 | $31.91 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $318.66 | $61.24 |
| 52 Week High | $426.75 | $212.71 |
| Indicator | HD | AZN |
|---|---|---|
| Relative Strength Index (RSI) | 33.58 | 64.53 |
| Support Level | N/A | $182.39 |
| Resistance Level | $393.75 | $211.32 |
| Average True Range (ATR) | 7.78 | 3.65 |
| MACD | 0.44 | 0.68 |
| Stochastic Oscillator | 12.94 | 86.49 |
Home Depot is the world's largest home improvement specialty retailer, operating 2,356 warehouse-format stores offering more than 30,000 products in store and 1 million products online in the US, Canada, and Mexico. Its stores offer building materials, home improvement products, lawn and garden products, and decor products and provide various services, including home improvement installation services and tool and equipment rentals. The acquisition of Interline Brands in 2015 allowed Home Depot to enter the MRO business, which has been expanded through the tie-up with HD Supply (2020). The 2024 tie-up with SRS will help grow professional demand in roofing, pool, and landscaping projects, while the 2025 purchase of GMS will lift building product sales, adding 1,200 distribution locations.
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.